{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:19:09Z","timestamp":1759479549262},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11938-006-0013-8","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T13:13:48Z","timestamp":1180876428000},"page":"314-323","source":"Crossref","is-referenced-by-count":14,"title":["Current gut-directed therapies for irritable bowel syndrome"],"prefix":"10.1007","volume":"9","author":[{"given":"Howard Y.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin C.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"13_CR1","first-page":"1910","volume":"97","author":"YA Saito","year":"2002","unstructured":"Saito YA, Schoenfeld P, Locke GR, III: The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002, 97:1910\u20131915.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"13_CR2","first-page":"II43","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl 2):II43-II47.","journal-title":"Gut"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","volume":"109","author":"L Agreus","year":"1995","unstructured":"Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671\u2013680.","journal-title":"Gastroenterology"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-133-2-200007180-00013","volume":"133","author":"J Jailwala","year":"2000","unstructured":"Jailwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136\u2013147.","journal-title":"Ann Intern Med"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","volume":"15","author":"T Poynard","year":"2001","unstructured":"Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355\u2013361.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","volume":"130","author":"B Lavo","year":"1987","unstructured":"Lavo B, Stenstam M, Nielsen AL: Loperamide in treatment of irritable bowel syndrome-a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987, 130:77\u201380.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","volume":"31","author":"PS Efskind","year":"1996","unstructured":"Efskind PS, Bernklev T, Vatn MH: A double-blind placebocontrolled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996, 31:463\u2013468.","journal-title":"Scand J Gastroenterol"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","volume":"130","author":"N Hovdenak","year":"1987","unstructured":"Hovdenak N: Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987, 130:81\u201384.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1365-2036.2004.02267.x","volume":"20","author":"D Lesbros-Pantoflickova","year":"2004","unstructured":"Lesbros-Pantoflickova D, Michetti P, Fried M, et al.: Metaanalysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1253\u20131269. A comprehensive, systematic review of treatment options available for IBS.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/BF02209014","volume":"40","author":"M Dapoigny","year":"1995","unstructured":"Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter doseresponse study. Dig Dis Sci 1995, 40:2244\u20132249.","journal-title":"Dig Dis Sci"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"G558","DOI":"10.1152\/ajpgi.00360.2002","volume":"284","author":"S Delgado-Aros","year":"2003","unstructured":"Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003, 284:G558-G566.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2036.2003.01670.x","volume":"18","author":"S Delgado-Aros","year":"2003","unstructured":"Delgado-Aros S, Chial HJ, Cremonini F, et al.: Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18:507\u2013514.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF02936952","volume":"32","author":"JH Liu","year":"1997","unstructured":"Liu JH, Chen GH, Yeh HZ, et al.: Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997, 32:765\u2013768.","journal-title":"J Gastroenterol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1572-0241.1998.00343.x","volume":"93","author":"MH Pittler","year":"1998","unstructured":"Pittler MH, Ernst E: Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998, 93:1131\u20131135.","journal-title":"Am J Gastroenterol"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2982.2005.00666.x","volume":"17","author":"LA Houghton","year":"2005","unstructured":"Houghton LA, Whorwell PJ: Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005, 17:500\u2013511.","journal-title":"Neurogastroenterol Motil"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2004.12.047","volume":"128","author":"B Salvioli","year":"2005","unstructured":"Salvioli B, Serra J, Azpiroz F, et al.: Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005, 128:574\u2013579.","journal-title":"Gastroenterology"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1572-0241.2003.07946.x","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412\u2013419. This randomized, placebo-controlled study showed that IBS is associated with small intestine bacterial overgrowth based on abnormal LBTs. IBS global symptoms were improved in 11% of placebo-treated patients and 35% of neomycin-treated patients. Subset analysis showed that 75% of neomycintreated patients who had LBTs that normalized reported global symptom improvement.","journal-title":"Am J Gastroenterol"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1365-2036.2005.02493.x","volume":"21","author":"G Nucera","year":"2005","unstructured":"Nucera G, Gabrielli M, Lupascu A, et al.: Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 21:1391\u20131395.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","volume":"101","author":"AI Sharara","year":"2006","unstructured":"Sharara AI, Aoun E, Abdul-Baki H, et al.: A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326\u2013333.","journal-title":"Am J Gastroenterol"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.14309\/00000434-200509001-00882","volume":"100","author":"M Pimenel","year":"2005","unstructured":"Pimenel M, Park S, Kong Y, et al.: Rifaximin, a nonabsorbable antibiotic, improves the symptoms of irritable bowel syndrome: a double-blinded randomized controlled study. Am J Gastroenterol 2005, 100:S324.","journal-title":"Am J Gastroenterol"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s10620-005-2570-4","volume":"50","author":"KL Dear","year":"2005","unstructured":"Dear KL, Elia M, Hunter JO: Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005, 50:758\u2013766.","journal-title":"Dig Dis Sci"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1572-0241.2000.02015.x","volume":"95","author":"S Nobaek","year":"2000","unstructured":"Nobaek S, Johansson ML, Molin G, et al.: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231\u20131238.","journal-title":"Am J Gastroenterol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","volume":"128","author":"L O\u2019Mahony","year":"2005","unstructured":"O\u2019Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541\u2013551.","journal-title":"Gastroenterology"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1365-2036.2003.01543.x","volume":"17","author":"HJ Kim","year":"2003","unstructured":"Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895\u2013904.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2982.2005.00695.x","volume":"17","author":"HJ Kim","year":"2005","unstructured":"Kim HJ, Vazquez Roque MI, Camilleri M, et al.: A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17:687\u2013696.","journal-title":"Neurogastroenterol Motil"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gut.25.2.168","volume":"25","author":"PA Cann","year":"1984","unstructured":"Cann PA, Read NW, Holdsworth CD: What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984, 25:168\u2013173.","journal-title":"Gut"},{"key":"13_CR27","first-page":"1416","volume":"52","author":"T Chiba","year":"2005","unstructured":"Chiba T, Kudara N, Sato M, et al.: Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil. Hepatogastroenterology 2005, 52:1416\u20131420.","journal-title":"Hepatogastroenterology"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0269-2813.2004.01862.x","volume":"19","author":"CJ Bijkerk","year":"2004","unstructured":"Bijkerk CJ, Muris JW, Knottnerus JA, et al.: Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 19:245\u2013251. A good review of the efficacy of fiber in treating C-IBS and the difference between soluble and insoluble fibers.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1572-0241.2002.05985.x","volume":"97","author":"JM Hebden","year":"2002","unstructured":"Hebden JM, Blackshaw E, D\u2019Amato M, et al.: Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol 2002, 97:2315\u20132320.","journal-title":"Am J Gastroenterol"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2036.2006.02705.x","volume":"23","author":"V Khoshoo","year":"2006","unstructured":"Khoshoo V, Armstead C, Landry L: Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006, 23:191\u2013196.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR31","doi-asserted-by":"crossref","unstructured":"Lubiprostone: RU 0211, SPI 0211. Drugs R D 2005, 6:245-248.","DOI":"10.2165\/00126839-200506040-00009"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1067\/mcp.2001.112680","volume":"69","author":"SS Liu","year":"2001","unstructured":"Liu SS, Hodgson PS, Carpenter RL, Fricke JR, Jr: ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001, 69:66\u201371.","journal-title":"Clin Pharmacol Ther"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1542-3565(05)00434-9","volume":"3","author":"J Gonenne","year":"2005","unstructured":"Gonenne J, Camilleri M, Ferber I, et al.: Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005, 3:784\u2013791.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2982.2005.00640.x","volume":"17","author":"M Camilleri","year":"2005","unstructured":"Camilleri M: Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005, 17:157\u2013165.","journal-title":"Neurogastroenterol Motil"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","volume":"118","author":"CM Prather","year":"2000","unstructured":"Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 2000, 118:463\u2013468.","journal-title":"Gastroenterology"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2036.2003.01449.x","volume":"17","author":"B Coffin","year":"2003","unstructured":"Coffin B, Farmachidi JP, Rueegg P, et al.: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003, 17:577\u2013585.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","volume":"15","author":"SA Muller-Lissner","year":"2001","unstructured":"Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655\u20131666.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","volume":"16","author":"J Novick","year":"2002","unstructured":"Novick J, Miner P, Krause R, et al.: A randomized, doubleblind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16:1877\u20131888. This large, multicenter, randomized, placebo-controlled trial showed that tegaserod is effective for alleviating global symptoms, bowel frequency, abdominal pain, and bloating in women with C-IBS.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","volume":"52","author":"J Kellow","year":"2003","unstructured":"Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671\u2013676.","journal-title":"Gut"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00365520310006748","volume":"39","author":"H Nyhlin","year":"2004","unstructured":"Nyhlin H, Bang C, Elsborg L, et al.: A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004, 39:119\u2013126.","journal-title":"Scand J Gastroenterol"},{"key":"13_CR41","first-page":"1361","volume":"351","author":"AD Brinker","year":"2004","unstructured":"Brinker AD, Mackey AC, Prizont R: Tegaserod and ischemic colitis. N Engl J Med 2004, 351:1361\u20131364.","journal-title":"N Engl J Med"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2036.2004.01903.x","volume":"19","author":"PD Higgins","year":"2004","unstructured":"Higgins PD, Davis KJ, Laine L: Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004, 19:729\u2013738.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","volume":"29","author":"PA Cann","year":"1984","unstructured":"Cann PA, Read NW, Holdsworth CD, Barends D: Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984, 29:239\u2013247.","journal-title":"Dig Dis Sci"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2036.2000.00762.x","volume":"14","author":"LA Houghton","year":"2000","unstructured":"Houghton LA, Foster JM, Whorwell PJ: Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000, 14:775\u2013782.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","volume":"13","author":"M Camilleri","year":"1999","unstructured":"Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149\u20131159.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","volume":"355","author":"M Camilleri","year":"2000","unstructured":"Camilleri M, Northcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035\u20131040.","journal-title":"Lancet"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","volume":"14","author":"KD Bardhan","year":"2000","unstructured":"Bardhan KD, Bodemar G, Geldof H, et al.: A doubleblind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000, 14:23\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","volume":"96","author":"T Lembo","year":"2001","unstructured":"Lembo T, Wright RA, Bagby B, et al.: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 96:2662\u20132670.","journal-title":"Am J Gastroenterol"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2001.21908","volume":"120","author":"M Camilleri","year":"2001","unstructured":"Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 2001, 120:652\u2013668.","journal-title":"Gastroenterology"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1572-0241.2003.07306.x","volume":"98","author":"NJ Talley","year":"2003","unstructured":"Talley NJ: Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003, 98:750\u2013758.","journal-title":"Am J Gastroenterol"},{"key":"13_CR51","unstructured":"Center for Drug Evaluation and Research: Lotronex (alosetron hydrochloride) Information. http:\/\/www.fda.gov\/ cder\/drug\/infopage\/lotronex\/lotronex.htm. Accessed February 24, 2005."},{"key":"13_CR52","doi-asserted-by":"crossref","unstructured":"Cilansetron: KC 9946. Drugs R D 2005, 6:169\u2013173.","DOI":"10.2165\/00126839-200506030-00005"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2036.2000.00757.x","volume":"14","author":"A Malcolm","year":"2000","unstructured":"Malcolm A, Camilleri M, Kost L, et al.: Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 2000, 14:783\u2013793.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR54","doi-asserted-by":"crossref","first-page":"G1468","DOI":"10.1152\/ajpgi.2001.281.6.G1468","volume":"281","author":"BE Viramontes","year":"2001","unstructured":"Viramontes BE, Malcolm A, Camilleri M, et al.: Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1468-G1476.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/cgh.2003.50019","volume":"1","author":"M Camilleri","year":"2003","unstructured":"Camilleri M, Kim DY, McKinzie S, et al.: A randomized, controlled exploratory study of clonidine in diarrheapredominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003, 1:111\u2013121.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","volume":"3","author":"JG Page","year":"1981","unstructured":"Page JG, Dirnberger GM: Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981, 3:153\u2013156.","journal-title":"J Clin Gastroenterol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-006-0013-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0013-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T13:48:08Z","timestamp":1587563288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-006-0013-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11938-006-0013-8","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"type":"print","value":"1092-8472"},{"type":"electronic","value":"1534-309X"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}